NASDAQ · Biotechnology

Vicore Pharma Holding AB (VCRE) Stock

$8.82 +1.85% NASDAQ: VCRE Healthcare

Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04.

Valuation

Metric	Value
Price	$8.82
Market Cap	$2.48B
P/E Ratio	-9.33
P/B Ratio	279.23
P/S Ratio	18579.40
EPS (TTM)	$-19.90
52-Week High	$17.80
52-Week Low	$7.88
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-48.25%
ROA	-284.14%
ROCE	-322.90%
Gross Margin	100.00%
Operating Margin	-11350.00%
Net Margin	-11925.00%
Debt/Equity	0.00
Current Ratio	12.68

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$109.0M	$4.0M
Operating Profit	$-33.0M	$-291.0M	$-322.0M	$-190.0M	$-454.0M
Net Profit	$-295.0M	$-288.0M	$-311.0M	$-169.0M	$-477.0M
EPS	$-0.47	$-38.82	$-31.80	$-12.30	$-19.90
Op Margin	—	—	—	-174.1%	-11905.8%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	—	—	—	—	$1.2B
Total Liabilities	—	—	—	—	$123.0M
Cash	—	—	—	—	$578.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

Jefferies Initiates Vicore Pharma Holding at Buy With $25 Price Target MT Newswires · Oct 9, 2026 Increase in Number of Shares and Votes in Vicore Pharma ACCESS Newswire · Sep 30, 2026 Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum ACCESS Newswire · Sep 17, 2026 Vicore Pharma to Participate in Upcoming Healthcare Conferences ACCESS Newswire · Sep 1, 2026 Vicore Pharma to Present at The Pareto Securities 17th Annual Healthcare Conference ACCESS Newswire · Aug 26, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-264.0M	$-300.0M	$-250.0M	$-165.0M	$-376.0M
Investing Cash Flow	$-7.0M	$71.0M	$-144.0M	$149.0M	$-601.0M
Financing Cash Flow	$0	$-13.0M	$-30.0M	$-48.0M	$-25.0M
Net Cash Flow	$2.0M	$-37.0M	$77.0M	$822.0M	$-578.0M
Free Cash Flow	$-264.0M	$-303.0M	$-250.0M	$-165.0M	$-376.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.26
EV / EBITDA	-99.17
FCF Yield	-0.91%
Quick Ratio	12.68
Interest Coverage	-31.05
Return 1Y	—
Return 3Y	—
Return 5Y	—

Ownership

Insiders Held0.00%

Institutions Held1.28%

Institutions Float Held1.28%

Institutional Holder	Shares	Report Date
Franklin Strategic Series-Franklin Biotechnology Discovery Fund	130,759	2026-07-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AVLNAvalyn Pharma Inc.	$26.04	-4.44%	-20.19	$1.15B	0.00%
LQDALiquidia Corporation	$42.65	+7.46%	19.28	$3.82B	0.00%

About Vicore Pharma Holding AB

Vicore Pharma Holding AB is headquartered in SE.

Vicore Pharma Holding AB (VCRE) stock trades at $8.82 with a market capitalization of $2.48B. The stock is valued at a negative price-to-earnings (P/E) ratio of -9.33, reflecting a net loss over the last twelve months, price-to-book of 279.23, price-to-sales of 18579.40. Over the past 52 weeks the stock has ranged between $7.88 and $17.80, and currently trades 50.4% below its 52-week high.

On profitability, Vicore Pharma Holding AB generates a return on equity (ROE) of -48.25% (negative, reflecting a net loss), return on capital employed of -322.90%, an operating margin of -11350.00%, a net profit margin of -11925.00%.

Official website: vicorepharma.com

Vicore Pharma Holding AB by the numbers, 2021–2025

Between 2021 and 2025 Vicore Pharma Holding AB reported revenue of $0 rising to $4.0M. Compounded, revenue has grown —% a year over five years, —% over three, -96.3% over the last twelve months. Net profit fell to $-477.0M.

The most recent net margin is -11925.00%. On a trailing twelve-month basis to Jun '26, revenue is $1.0M and net profit $-273.0M.

Borrowings stand at $0, cash on hand is $93.4M, cash from operations was $-376.0M in the latest year, positive in 0 of the last 5.

Return on equity has averaged -43.6% over five years, and was -43.6% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Vicore Pharma Holding AB (VCRE) — frequently asked questions

What is Vicore Pharma Holding AB (VCRE) stock price today?

Vicore Pharma Holding AB (VCRE) is currently trading at $8.82, up 1.85% today.

What is VCRE P/E ratio?

Vicore Pharma Holding AB's P/E ratio is -9.33. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is VCRE return on equity (ROE)?

Vicore Pharma Holding AB's return on equity (ROE) is -48.25%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Vicore Pharma Holding AB's market cap?

Vicore Pharma Holding AB has a market capitalization of $2.48B.

Does VCRE pay a dividend?

Vicore Pharma Holding AB is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does VCRE carry?

Vicore Pharma Holding AB has a debt-to-equity ratio of 0.00. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is VCRE's profit margin?

Vicore Pharma Holding AB reports a net profit margin of -11925.00% — the share of revenue left after every cost, including tax and interest.

What sector is VCRE in?

Vicore Pharma Holding AB is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is VCRE listed on?

Vicore Pharma Holding AB trades on NASDAQ under the ticker VCRE.

What is VCRE's 52-week range?

Over the last year Vicore Pharma Holding AB has traded between $7.88 and $17.80.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Screens VCRE currently matches

On the figures above, Vicore Pharma Holding AB passes the filters for 10 of our ready-made screens, among them Low Debt Stocks, Stocks Under $10, Debt Free Stocks Under $100. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Low Debt Stocks Stocks Under $10 Debt Free Stocks Under $100 Debt Free Stocks Stocks Under $100 Stocks Under $50 High Gross Margin Stocks Mid Cap Stocks Debt to Equity Below 1 Stocks High Current Ratio Stocks

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.